Can a cancer drug help people with HIV pause their daily meds?

NCT ID NCT06660498

Ongoing Disease control Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether pomalidomide, a drug currently used for multiple myeloma, can help control HIV when people temporarily stop their standard antiretroviral therapy (ART). Thirty-two adults with well-controlled HIV will receive either pomalidomide or a placebo alongside low-dose aspirin. The goal is to see if pomalidomide can delay the need to restart ART by boosting the immune system's ability to suppress the virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pomalidomide
What this could lead to: If it works, this could point toward a way for people with HIV to safely stop daily antiretroviral therapy for longer periods.
What could go wrong: This is an early-phase trial with only 32 participants, so results may not apply broadly. Pomalidomide can cause serious side effects, and the treatment interruption carries risks of viral rebound.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Aarhus University Hospital

Aarhus, Denmark
Royal Melbourne Hospital

Melbourne, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.